FDA’s Gottlieb proposes biosimilar pathway to tackle skyrocketing insulin prices

Insulin prices have shot up nearly 600 percent, according to a congressional study, leading to potentially deadly rationing by many patients.

Article Source: FDA’s Gottlieb proposes biosimilar pathway to tackle skyrocketing insulin prices.